We retrospectively analyzed serological test results for anti-hepatitis A virus immunoglobulin G (anti-HAV IgG) of sera collected from 779 military personnel during January 2001 to May 2008. The overall seroprevalence of anti-HAV IgG of the subjects was 17.5% (95% confidence interval [CI], 14.8-20.1%). When adjusted to the age-specific distribution of the army population, the age-adjusted seroprevalence was 14.6% (95% CI, 13.0-16.3%). All subjects who were 40 years and over had anti-HAV IgG. Meanwhile, the seroprevalence of anti-HAV IgG for those 24 years and younger was 4.7%. This low prevalence rate among young military personnel calls for stricter adherence to vaccination policies and stronger requirements for military HAV vaccination programs.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hepatitis A virus infection and seroprevalence, Istanbul, Turkey, 2020-2023.
Ann Saudi Med
December 2024
From the Department of Virology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Background: Hepatitis A infections continue to be a major global public health problem. The epidemiology and seroprevalence of hepatitis A virus (HAV) have important public health implications. This study aimed to retrospectively examine the hepatitis A cases and hepatitis A seroprevalence in our region in our hospital with the highest number of inpatient and outpatient cases in Istanbul.
View Article and Find Full Text PDFBiologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Prevalence of hepatitis A and B antibodies among enlisted accessions, Joint Base San Antonio-Lackland, 2023.
MSMR
October 2024
Uniformed Services University of the Health Sciences, Department of Preventive Medicine and Biostatistics, Bethesda, MD.
Article Synopsis
- The Department of the Air Force conducts antibody testing for hepatitis B and hepatitis A among new recruits at basic training in San Antonio.
- The results, alongside vaccination records, inform vaccination strategies during training.
- Analysis from 2023 indicates a significantly higher presence of hepatitis A antibodies compared to hepatitis B antibodies in the trainee population.
Prevalence of hepatitis among young men who have sex with men and transgender women in Brazil.
Rev Saude Publica
October 2024
Universidade Federal da Bahia. Instituto de Saúde Coletiva. Salvador, BA, Brasil.
Article Synopsis
- This study investigates viral hepatitis prevalence among young men who have sex with men (MSM) and transgender women (TGW) in three Brazilian cities, focusing on those aged 15-19.
- The research collected data through social behavioral questionnaires and blood tests to check for hepatitis A, B, and C antibodies and active infections.
- Results showed 17.7% had immunity to hepatitis A, while hepatitis B and C prevalence was lower at 2.8% and 0.2%, respectively, indicating a need for improved vaccination and treatment strategies in these populations.
The Immunological and Epidemiological Effectiveness of Pediatric Single-Dose Vaccination against Hepatitis A 9 to 11 Years after Its Implementation in the Tyva Republic, the Russian Federation.
Vaccines (Basel)
August 2024
Laboratory of Viral Hepatitis, Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.
Since 2012, universal single-dose HAV vaccination in children aged 3 years and older has been implemented in the Tyva Republic, a region of the Russian Federation. The aim of this prospective non-interventional observational single-center study was to determine the immunological and epidemiological effectiveness of single-dose vaccination against hepatitis A 9 to 11 years after its implementation. The anti-HAV IgG antibodies were determined in two independent cohorts of children who were vaccinated with a single dose of monovalent pediatric inactivated vaccine (HAVRIX 720 EU) in Tyva in 2012 and recruited 9 years (Year 9 Cohort) and 11 years (Year 11 Cohort) after immunization.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!